Velpatasvir and Sofosbuvir · VELPATASVIR 100 mg/1; SOFOSBUVIR 400 mg/1 · Tablet, Film Coated · Oral · Gilead Sciences, Inc.
NDC 61958-2201-01 · 28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC · NDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The brand price has held steady around $866.40 per unit over the past year. Generic versions run $278.05 per unit — 3.1× cheaper. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | PED | Sep 19, 2027 |
| exclusivity | PED | Sep 19, 2027 |
| exclusivity | ODE-293 | Mar 19, 2027 |
| exclusivity | ODE-293 | Mar 19, 2027 |
| patent | 11116783*PED | Jul 30, 2034 |
| patent | 9757406*PED | Jul 30, 2034 |
| patent | 10086011*PED | Jul 30, 2034 |
| patent | 11116783*PED | Jul 30, 2034 |
| patent | 9757406*PED | Jul 30, 2034 |
| patent | 10086011*PED | Jul 30, 2034 |
| patent | 9757406 | Jan 30, 2034 |
| patent | 10086011 | Jan 30, 2034 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Patheon Inc. | VELPATASVIR 100 mg/1; SOFOSBUVIR 400 mg/1 | Aug 20, 2026 | Sep 3, 2026 |
| Asegua Therapeutics LLC | VELPATASVIR 100 mg/1; SOFOSBUVIR 400 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Gilead Sciences, Inc. | VELPATASVIR 50 mg/1; SOFOSBUVIR 200 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Gilead Sciences, Inc. | VELPATASVIR 100 mg/1; SOFOSBUVIR 400 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Asegua Therapeutics LLC | VELPATASVIR 400 mg/1; SOFOSBUVIR 100 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Gilead Sciences, Inc. | VELPATASVIR 400 mg/1; SOFOSBUVIR 100 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Gilead Sciences, Inc. | VELPATASVIR 200 mg/1; SOFOSBUVIR 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Patheon Inc. | VELPATASVIR 400 mg/1; SOFOSBUVIR 100 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Asegua Therapeutics LLC | SOFOSBUVIR 400 mg/1; VELPATASVIR 100 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Gilead Sciences, Inc. | SOFOSBUVIR 400 mg/1; VELPATASVIR 100 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Gilead Sciences, Inc. | SOFOSBUVIR 200 mg/1; VELPATASVIR 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Patheon Inc. | SOFOSBUVIR 400 mg/1; VELPATASVIR 100 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Epclusa — NDC 61958-2201-01," retrieved September 3, 2026, https://drugdashboards.com/drug/61958220101.
Free to cite with attribution — see how the data is put together.